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The understanding of factors underlying the incomplete penetrance and variable expressivity of ARVC remains poorly understood. Nevertheless, their identification is highly important for the diagnosis, risk stratification and prognosis of relatives in ARVC families and remains an important challenge. Reduced penetrance has been shown to be sex-and age-related, with an overrepresentation of men in probands [3, 6] . Other environmental factors such as intensive practice of sports or virus have been suggested [7] , and genetic factors are also involved. The presence of multiple mutations/genetic variants is associated with an increased penetrance and a more severe phenotype [1, 8] . Nevertheless, the role of genetic modifying factors, especially rare desmosomal missense variants, remains poorly understood and still needs to be further investigated in larger population studies [9] . These variants are indeed frequent in the general population (5% of Caucasians) and their pathogenic role is still debated in the absence of a proven functional effect [10] . The genetic heterogeneity of desmosomal gene mutations, the strong genetic background of rare missense variants in the general population and the small size of families make the study of putative genetic modifying factors difficult. The identification in the Dutch population of frequent mutations with a founder effect provides a more homogenous population, with a large number of individuals carrying the same mutation that could be a useful tool to study such factors. In addition, the reduced penetrance observed as associated with this mutation [5] is in line with a founder effect of a mutation that is supposed to have limited consequences on reproductive fitness and life expectancy, and can be transmitted for more than seven generations.
Van der Smagt et al. [5] also discuss the mutational mechanism associated with splice site PKP2 mutations. PKP2 mutations are predominantly truncating, leading to a putative haplo-insufficiency mechanism. However, there is a lack of functional data on the mechanisms underlying splice-site and missense PKP2 mutations. Although splice-site mutations can lead to an abnormal mRNA escaping the nonsense-mediated messenger RNA decay, there is no evidence that the abnormal protein could have a dominant negative effect. Some data suggest that haplo-insufficiency could be the major ARVC-causing mutation mechanism, including nontruncating mutations. A functional study of a missense PKP2 mutation has shown that the mutated PKP2 presented no dominant negative effect on mature desmosomes but displayed an increased turnover and a premature degradation suggesting, at least partly, a haplo-insufficiency mechanism [11] . Other data from a knock-in animal model homozygous for a mutated DSG2 lacking the extracellular domain showed a decrease of total DSG2 amount, suggesting degradation of the abnormal protein [12] . We could hypothesize that abnormal PKP2 proteins secondary to aberrant splicing could also lead to premature PKP2 degradation. The identification of the mutational mechanism of such mutations needs further in vivo investigations with the characterization of the mutated PKP2 in cardiac tissue, including Western blot analyses. However, the access to heart tissue from mutation carriers remains limited. The recent possibility of obtaining induced pluripotent stem cells from human fibroblasts (from a skin biopsy for instance) could provide a useful human heterozygous in vitro model to study the consequences of mutations on protein expression and function. The identification of the mutational mechanisms associated with desmosomal gene mutations is indeed critical for a better understanding of ARVC physiopathology and for the development of future therapeutic strategies.
